Text Size:AAA

Monoclonal Antibody Targets for Cancer Immunotherapy

Monoclonal Antibody Targets Collection for Cancer Immunotherapy

ERBB2 EGFR VEGFA CTLA-4 PD-1 PD-L1
CD19 CD20 CD30 CD33 CD52 Mucins
CD40 CD137 TGFβ CD25 CEA ERBB3/HER3
FAP vEGFR2 HER4/ERBB4 OX40 gpA33 CAIX
EpCAM IGF1R CCR4 EPHA3 PSMA RANKL
Folate receptor-α GITR LAG3 TIM-3 TRAILR1 TRAILR2
mesothelin          

Monoclonal Antibody Targets for Cancer Immunotherapy: HER2

The HER2 gene, located adjacent to the topoisomerase IIa genes, is related to the oncogene v-erbB of the avian erythroblastosis virus. In carcinomas, HER2 acts as an oncogene, mainly because highlevel amplification of the gene induces protein overexpression in the cellular membrane and subsequent acquisition of advantageous properties for a malignant cell.
A role of HER2 in the development of numerous types of human cancer has been indicated by many studies. HER2 overexpression and/or amplification have been detected in 10%–34% of invasive breast cancers and correlate with the clinical outcome, confer poor prognosis, and also constitute a predictive factor of poor response to chemotherapy and endocrine therapy. HER2 overexpression and/or amplification have also been observed in colon, bladder, ovarian, endometrial, lung, uterine cervix, head and neck, esophageal, and gastric carcinomas.

Monoclonal Antibody Targets for Cancer Immunotherapy: PD-1

Programmed death 1 (PD-1) is a key immune-checkpoint receptor expressed by activated T cells, and it mediates immunosuppression. PD-1 functions primarily in peripheral tissues, where T cells may encounter the immunosuppressive PD-1 ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which are expressed by tumor cells, stromal cells, or both. Inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity.

Monoclonal Antibody Targets for Cancer Immunotherapy: VEGFA

Growth of solid tumours is accompanied by stimulation of angiogenesis. Vascular endothelial growth factor-A (VEGFA; also referred to as VEGF) is one, but not the only, primary factor driving expansion of the tumour vascular bed. It is well established that the tumour microvasculature displays abnormal features, including high turnover of vessels, poor perfusion and increased leakage. In many instances vascular 'normalization', i.e. reversal of these abnormalities in response to antiangiogenic treatment, has been reported to lead to decreased tumour growth, despite the fact that the normalized tumour vessels appear more functional.

Monoclonal Antibody Targets for Cancer Immunotherapy: Reference

Claesson‐Welsh L, Welsh M. VEGFA and tumour angiogenesis[J]. Journal of internal medicine, 2013, 273(2): 114-127.
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target[J]. Annals of Oncology, 2008, 19(9): 1523-1529.

請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”